Autolus Therapeutics plc American Depositary Share (AUTL) is a publicly traded Healthcare sector company. As of May 21, 2026, AUTL trades at $1.65 with a market cap of $479.06M and a P/E ratio of -1.48. AUTL moved -0.31% today. Year to date, AUTL is -12.90%; over the trailing twelve months it is +5.88%. Its 52-week range spans $1.11 to $5.00. Analyst consensus is strong buy with an average price target of $8.08. Rallies surfaces AUTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Autolus Cuts 13% Workforce, Seeks $15M Savings and $120–135M 2026 Revenue: Autolus Therapeutics will cut headcount by about 13% while doubling manufacturing output for commercial and clinical trial patients in 2026. The company reiterated full-year 2026 AUCATZYL net revenue guidance of $120–$135 million (up from $74 million in 2025) and anticipates achieving positive gross margin next year.
| Metric | Value |
|---|---|
| Price | $1.65 |
| Market Cap | $479.06M |
| P/E Ratio | -1.48 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.00 |
| 52-Week Low | $1.11 |
| Volume | 1.25K |
| Avg Volume | 0 |
| Revenue (TTM) | $92.62M |
| Net Income | $-288.96M |
| Gross Margin | -11.19% |
6 analysts cover AUTL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.08.